Previous 10 | Next 10 |
2023-11-13 13:58:11 ET Summary Corcept Therapeutics' strategic shift to relacorilant from Korlym addresses efficacy and safety, amidst Teva's patent dispute. Financially robust with 21.5% YOY revenue growth; however, increasing R&D costs and potential generic competition are c...
2023-11-13 09:51:59 ET More on Royalty Pharma, Teva, etc. Royalty Pharma: Post Q3 Earnings, We Reiterated Our Strong Buy Royalty Pharma PLC (RPRX) Q3 2023 Earnings Call Transcript Teva Pharmaceutical Industries Limited (TEVA) Q3 2023 Earnings Call Transcript ...
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophrenia Phase 3 data expected in the second half of 2024 NEW YORK and TEL AVIV, Israel, Nov. ...
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophrenia Phase 3 data expected in the second half of 2024 Teva Pharmaceuticals Internation...
2023-11-08 12:48:09 ET Teva Pharmaceutical Industries (TEVA) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Investor Relations Richard Francis - President and Chief Executive Officer, Member of the ...
2023-11-08 09:04:00 ET U.S. stock index futures on Wednesday pointed to a marginally higher open, a day after Wall Street's benchmark S&P 500 ( SP500 ) gauge posted its best daily win streak since November 2021. Market participants parsed through a host of earnings reports while loo...
2023-11-08 08:15:34 ET More on Teva Teva Pharmaceutical Industries Limited 2023 Q3 - Results - Earnings Call Presentation Teva: Focus On Innovation And Growth Means The Times They Are A Changing Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 21st Annual...
2023-11-08 07:03:48 ET More on Teva Pharmaceutical Teva: Focus On Innovation And Growth Means The Times They Are A Changing The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider Teva appoints R. Ananth as CEO of Teva API division For ...
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion Global revenues of $3.9 billion, reflect an increase of 7% from the third quarter of 2022 Increased revenues reflect sustained growth of AUSTEDO ® , AJOVY ® and global generics business: ...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...